Parameter | Univariate variables | Multivariate model | ||
---|---|---|---|---|
OR (95% CI) | p value | OR (95% CI) | p value | |
Age in years (> 65 vs ≤ 65) | 1.12 (0.32–3.90) | 0.85 | ||
Location (intra- vs extra-canalicular) | 2.10 (0.46–9.64) | 0.33 | ||
Cystic component (yes vs no) | 1.10 (0.24–5.04) | 0.89 | ||
Target volume (> vs ≤ 6.1 cm3) | 4.85 (1.43–16.49) | 0.01 | 2.84 (0.53–15.04) | 0.21 |
Target minimum dose | 0.85 (0.27–2.67) | 0.80 | ||
Target mean dose | 0.72 (0.23–2.24) | 0.57 | ||
Target maximum dose | 0.51 (0.16–1.61) | 0.25 | ||
Pre-SRS tumor growth (yes vs no) | 2.02 (0.56–7.31) | 0.28 | ||
Koos grade (III–IV vs I–II) | 3.45 (1.01–11.81) | 0.04 | 2.41 (0.41–14.24) | 0.33 |
Pre-SRS tinnitus (yes vs no) | 1.33 (0.38–4.67) | 0.65 | ||
Pre-SRS dizziness (yes vs no) | 3.98 (1.19–13.24) | 0.02 | 4.15 (1.00–17.20) | 0.05 |
Vestibule minimum dose | 1.55 (1.03–2.32) | 0.03 | 1.75 (1.05–2.89) | 0.02 |
Vestibule mean dose | 1.10 (0.89–1.35) | 0.35 | ||
Vestibule maximum dose | 1.01 (0.86–1.19) | 0.82 | ||
Transient volume expansion (yes vs no) | 1.96 (0.58–6.61) | 0.27 | ||
Novalis vs Cyberknife | 0.47 (0.14–1.55) | 0.21 |